DOCSLIB.ORG

The Role of Amphotericin B Alone and in Combination with Different Antibiotics and Antifungals on Biofilms Produced by Candida Species

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Amphotericin B Alone and in Combination with Different Antibiotics and Antifungals on Biofilms Produced by Candida Species FABAD J. Pharm. Sci., 45, 2, 117-124, 2020 RESEARCH ARTICLE The Role of Amphotericin B Alone and in Combination with Different Antibiotics and Antifungals on Biofilms Produced by Candida Species Mayram HACIOGLU*° , Ozlem OYARDI** , Berna OZBEK-CELIK*** The Role of Amphotericin B Alone and in Combination with Amfoterisin B’nin Tek Başına ve Çeşitli Antibiyotik ve Different Antibiotics and Antifungals on Biofilms Produced Antifungallerle Birlikte Candida Biyofilmleri Üzerine Etkisi by Candida Species SUMMARY ÖZ Biofilm formation by Candida species is highly resistant to commonly Biyofilm oluşumu Candida türlerinde antifungallere daha dirençli used antifungal agents and is difficult to treat. Therefore, this study olmalarını sağladığından tedavisi güç enfeksiyonlara neden focused on effectiveness of combination therapy against Candida olmaktadır. Bu amaçla, bu çalışmada Candida biyofilmlerine biofilms. The antimicrobial activities of amphotericin B (1 µg/ karşı kombinasyon tedavisinin etkinliği araştırılmıştır. ml or 10 µg/ml) alone or in combination with various antibiotics Amfoterisin B’nin (1 µg / ml veya 10 µg / ml) tek başına veya (doxycycline (20 µg/ml), tigecycline (20 µg/ml), colistin (30 µg/ml), çeşitli antibiyotiklerle [(doksisiklin (20 µg / ml), tigesiklin (20 µg / rifampicin (120 µg/ml), ciprofloxacin (20 µg/ml)) or antifungals ml), kolistin (30 µg / ml), rifampisin (120 µg / ml), siprofloksasin (clotrimazole (2.5 µg/ml), anidulafungin (10 µg/ml), caspofungin (20 µg / ml)] veya çeşitli antifungaller [(klotrimazol (2.5 µg / ml), (10 µg/ml), itraconazole (2.5 µg/ml) and fluconazole (10 µg/ml)) anidulafungin (10 µg / ml), kaspofungin (10 µg / ml), itrakonazol were investigated against fungal biofilms produced by C. albicans (2.5 µg / ml), flukonazol (10 µg/ml)] ile kombinasyonlarının SC5314, C. tropicalis ATCC 750 and C. parapsilosis ATCC C. albicans SC5314, C. tropicalis ATCC 750 ve C. parapsilosis 22019. Fungal viability was monitored by culture (colony-forming ATCC 22019 tarafından üretilen biyofilmlere karşı etkinlikleri unit (CFU). According to the results, rifampicin and ciprofloxacin araştırılmıştır. Sonuçlarımız rifampisin ve siprofloksasinin, enhanced the activity of amphotericin B (10 µg/ml). Among the amfoterisin B’nin (10 µg / ml) aktivitesini arttırdığını, antifungals, clotrimazole displayed the most significant effect in antifungaller arasında ise klotrimazol ve amfoterisin B (10 µg combination with amphotericin B (10 µg/ml), especially against C. / ml) kombinasyonunun özellikle C. parapsilosis biyofilmlerine parapsilosis biofilms. karşı etkili olduğunu göstermiştir. Sonuç olarak, amfoterisin B Consequently, combinations of amphotericin B and antibiotic or ve antibiyotik veya antifungal kombinasyonları Candida spp. antifungal could be a promising option for the treatment of Candida biyofilmlerinin tedavisi için ümit verici bir seçenek olabileceği biofilms. düşünülmüştür. Key Words: Candida, Biofilm, Amphotericin B, Clotrimazole, Anahtar Kelimeler: Candida, Biyofilm, Amfoterisin Antifungal combinations, Antibiotics combinations. B, Klotrimazol, Antifungal kombinasyonu, Antibiyotik kombinasyonu. Received: 18.07.2019 Revised: 12.11.2019 Accepted: 25.12.2019 * ORCID: 0000-0003-0823-631X Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Beyazit, Istanbul, ** ORCID: 0000-0001-9992-7225 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Beyazit, Istanbul, *** ORCID: 0000-0001-8909-8398 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Beyazit, Istanbul, ° Corresponding Author; Mayram HACIOGLU Phone: + 90 212 440 00 00 /13522, E-mail: [email protected] 117 Hacioğlu, Oyardi, Özbek-Çelik INTRODUCTION are required to combat biofilm-related Candida in- Candida species are opportunistic pathogens that fections (Taff et al., 2013). The aim of this study was reside in the human oral cavity, vagina, and gastro- to evaluate the in vitro effects of antibacterial agents intestinal tract natural microbiota (Cho et al., 2014; and traditional antifungals, both alone and in combi- nation with amphotericin B against mature biofilms Kumamoto, 2011). Infections caused by Candida produced by C. albicans SC5314, C. tropicalis ATCC species range from superficial infections to invasive 750 and C. parapsilosis ATCC 22019. infections including candidiasis and endocarditis, that frequently occur in immunocompromised and MATERIALS AND METHODS hospitalized patients. Drug abuse, organ transplanta- Strains and growth conditions tion, surgery, burns, and malignancies are major risk The three most common biofilm-forming Can- factors for invasive Candida infections and thus affect dida species, reference isolates C. albicans SC5314 morbidity and mortality rates. Candida albicans is (ATCC MYA-2876), C. tropicalis ATCC 750 and C. identified as the predominant pathogen in Candida parapsilosis ATCC 22019 were used in this study. All species infections. Nevertheless, recently non-Candi- three isolates are susceptible to the antifungals used da albicans Candida (NCAC) species, such as C. trop- in this study. Isolates were sub-cultured from frozen icalis and C. parapsilosis, are increasing in prevalence stocks onto Sabouraud dextrose agar (SDA, Difco, (Diba et al., 2018; Fesharaki et al., 2013; Yesilkaya et Sparks, MD, USA) plates and incubated at 30°C over- al., 2017). night to generate cultures for use in the following ex- Candida species biofilms are virulence factors periments. Yeast extract peptone dextrose (YPD, Sig- that promote infection especially when the host de- ma-Aldrich, St. Louis, MO, USA) agar and broth, and fense system is impaired during treatment. Microor- Roswell Park Memorial Institute (RPMI, Sigma-Al- ganisms form biofilms as a survival strategy. Biofilm drich, St. Louis, MO, USA) medium, supplemented embedded microorganisms possess resistance to both with L-glutamine and buffered with morpholinepro- antimicrobial agents and host immune responses panesulfonic acid (MOPS; Sigma-Aldrich, St. Louis, when compared to their planktonic forms. Antimi- MO, USA), was used in the biofilm assays. crobial resistance is mainly due to low penetration Antimicrobial agents of antibiotics into biofilm matrix, low oxygen and nutrient concentrations, and expression of biofilm Amphotericin B deoxycholate (purity; 99,8%, specific genes (Taff et al., 2013). Candida species can Bristol-Myers Squibb, New York, USA), clotrimazole cause life-threatening problems by forming biofilms (purity; 99,97 %, Bristol-Myers Squibb, New York, on the surfaces of medical devices such as implants, USA), fluconazole (purity; 99,8%, Pfizer, New York, heart valves, catheters, and ocular lenses (Kojic and USA), anidulafungin (purity; 98,8%, Pfizer, New Darouiche, 2004). Moreover, Candida biofilms pose York, USA), caspofungin (purity; 100%, Merck Sharp Dohme, Kenilworth, NJ, USA), itraconazole (purity; a significant risk in cystic fibrosis (Chotirmall et al., 100%, Sigma Aldrich, St. Louis, MO, USA), doxycy- 2010; Williams et al., 2016). Previous studies have cline (purity; 98,9 %, Kocak Pharma Ilac, Turkey), shown that 60-70% of the Candida isolates from dif- tigecycline (purity; 99,7%, Wyeth Pharmaceuticals, ferent clinical materials produce biofilm (Tellapraga- Madison, NJ, USA), colistin (purity; 100%, Sigma da et al., 2014). Aldrich, St. Louis, MO, USA), rifampicin (purity; The absence of appropriate antifungal therapy is a 99,99%, Kocak Pharma Ilac, Turkey) and ciprofloxa- major contributor to the increasing mortality, as well cin (purity; 99,99%, Kocak Pharma Ilac, Turkey) were as hospital length of stay and cost of the treatment, in obtain from the manufacturers. Stock solutions were Candida infections. One of the most preferred anti- prepared at 1280 mg/L for the antifungals and 5120 fungal agents in the clinical practice is amphotericin mg/L for the antibiotics, according to Clinical and B. Amphotericin B is a polyene class antifungal that Laboratory Standards Institute (CLSI) (CLSI, 2006; acts by binding to ergosterol in the cell membrane. CLSI 2012; CLSI 2014) and stored at -80°C for up to Susceptibility studies indicate that Candida biofilms 6 months. The final concentrations of antimicrobial may be up to 1000-times more resistant than plank- agents used for biofilm assay were their peak serum tonic cells to antimicrobial agents (Tobudic et al., concentration (Cmax) values after intravenous drug 2012), resulting in potentially high toxicity to host administration. Antifungal agents’ susceptibility was cells (Mazu et al., 2016). Therefore, new drug strat- performed by broth dilution according to CLSI rec- egies, therapies and synergistic drug combinations ommendations. All strains were determined as sus- 118 FABAD J. Pharm. Sci., 45, 2, 117-124, 2020 ceptible to anidulafungin (≤2 µg/ml), caspofungin (≤2 (900 rpm) and sonication (both 5 min) (Meddison). µg/ml), itraconazole (<0.125 µg/ml) and fluconazole The well contents were collected into sterile tubes and (<8 µg/ml). C. parapsilosis ATCC 22019 was used as vortexed and sonicated again after the addition of 200 the susceptibility test control strain (CLSI, 2012). µl PBS. To enumerate the pathogen load cultures were Biofilm formation serially diluted in sterile PBS and plated onto SDA us- ing the drop plate method. Plates were incubated at Biofilms were formed in microtiter plates wells 37 °C for 24 h and colonies counted and expressed as as previously described by Ramage et al. (2001) [18].
Load more

Recommended publications
  • Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
    animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 OFFICE DIRECTOR MEMO Deputy Office Director Decisional Memo Page 2 of 17 NDA 204,684 Miltefosine Capsules 1. Introduction Leishmania organisms are intracellular protozoan parasites that are transmitted to a mammalian host by the bite of the female phlebotomine sandfly. The main clinical syndromes are visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (ML). VL is the result of systemic infection and is progressive over months or years. Clinical manifestations include fever, hepatomegaly, splenomegaly, and bone marrow involvement with pancytopenia. VL is fatal if untreated. Liposomal amphotericin B (AmBisome®) was FDA approved in 1997 for the treatment of VL. CL usually presents as one or more skin ulcers at the site of the sandfly bite. In most cases, the ulcer spontaneously resolves within several months, leaving a scar. The goals of therapy are to accelerate healing, decrease morbidity and decrease the risk of relapse, local dissemination, or mucosal dissemination. There are no FDA approved drugs for the treatment of CL. Rarely, CL disseminates from the skin to the naso-oropharyngeal mucosa, resulting in ML. ML can also develop some time after CL spontaneous ulcer healing. The risk of ML is thought to be highest with CL caused by the subgenus Viannia. ML is characterized in the medical literature as progressive with destruction of nasal and pharyngeal structures, and death may occur due to complicating aspiration pneumonia. There are no FDA approved drugs for the treatment of ML. Paladin Therapeutics submitted NDA 204, 684 seeking approval of miltefosine for the treatment of VL caused by L.
    [Show full text]
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives
    Current Fungal Infection Reports (2019) 13:45–58 https://doi.org/10.1007/s12281-019-00338-6 PHARMACOLOGY AND PHARMACODYNAMICS OF ANTIFUNGAL AGENTS (N BEYDA, SECTION EDITOR) Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives Ruchi Thakkar1,2 & Akash Patil1,2 & Tabish Mehraj1,2 & Narendar Dudhipala1,2 & Soumyajit Majumdar1,2 Published online: 2 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review In this review, a compilation on the current antifungal pharmacotherapy is discussed, with emphases on the updates in the formulation and clinical approaches of the routinely used antifungal drugs in ocular therapy. Recent Findings Natamycin (Natacyn® eye drops) remains the only approved medication in the management of ocular fungal infections. This monotherapy shows therapeutic outcomes in superficial ocular fungal infections, but in case of deep-seated mycoses or endophthalmitis, successful therapeutic outcomes are infrequent, as a result of which alternative therapies are sought. In such cases, amphotericin B, azoles, and echinocandins are used off-label, either in combination with natamycin or with each other (frequently) or as standalone monotherapies, and have provided effective therapeutic outcomes. Summary In recent times, amphotericin B, azoles, and echinocandins have come to occupy an important niche in ocular antifungal pharmacotherapy, along with natamycin (still the preferred choice in most clinical cases), in the management of ocular fungal infections.
    [Show full text]
  • Enhanced Activity of Antifungal Drugs Using Natural Phenolics Against Yeast Strains of Candida and Cryptococcus N.C.G.Faria1, J.H
    Letters in Applied Microbiology ISSN 0266-8254 ORIGINAL ARTICLE Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus N.C.G.Faria1, J.H. Kim3, L.A.P. Gonc¸alves2, M. de L. Martins1, K.L. Chan3 and B.C. Campbell3 1 Instituto de Higiene e Medicina Tropical ⁄ CREM, Universidade Nova de Lisboa, Portugal 2 Instituto de Higiene e Medicina Tropical ⁄ CEAUL, Universidade Nova de Lisboa, Portugal 3 Plant Mycotoxin Research Unit, Western Regional Research Center, ARS-USDA, Albany, CA, USA Keywords Abstract amphotericin B, phenolic, synergism, triazole. Aims: Determine whether certain, natural phenolic compounds enhance activ- Correspondence ity of commercial antifungal drugs against yeast strains of Candida and Crypto- Bruce C. Campbell, Plant Mycotoxin Research coccus neoformans. Unit, Western Regional Research Center, Methods and Results: Twelve natural phenolics were examined for fungicidal USDA-ARS, 800 Buchanan Street, Albany, CA activity against nine reference strains of Candida and one of C. neoformans. Six 94710, USA. compounds were selected for synergistic enhancement of antifungal drugs, E-mail: [email protected] amphotericin B (AMB), fluconazole (FLU) and itraconazole (ITR). Matrix assays 2010 ⁄ 1438: received 19 August 2010, revised of phenolic and drug combinations conducted against one reference strain, each, 14 February 2011 and accepted 15 February of Candida albicans and C. neoformans showed cinnamic and benzoic acids, thy- 2011 mol, and 2,3- and 2,5-dihydroxybenzaldehydes (-DBA) had synergistic interac- tions depending upon drug and yeast strain. 2,5-DBA was synergistic with doi:10.1111/j.1472-765X.2011.03032.x almost all drug and strain combinations.
    [Show full text]
  • Antifungal Drugs
    Antifungal Drugs Antifungal or antimycotic drugs are those agents used to treat diseases caused by fungus. Fungicides are drugs which destroy fungus and fungistatic drugs are those which prevent growth and multiplication of fungi. Collectively these drugs are often referred to as antimycotic or antifungal drugs. General characteristics of fungus: Fungi of medical significance are of two groups: Yeast Unicellular (Candida, Crytococcus) Molds Multicellular; filamentous consist of hyphae (Aspergillus, Microsporum, Trichophyton) They are eukaryotic i.e. they have well defined nucleus and other nuclear materials. They are made of thin threads called hyphae. The hyphae have a cell wall (like plant cells) made of a material called chitin. The hyphae are often multinucleate. They do not have chlorophyll, can’t make own food by photosynthesis, therefore derive nutrients by means of saprophytic or parasitic existence. Cell membrane is made up of ergosterol. Types of fungal infections: Fungal infections are termed as mycoses and in general can be divided into: Superficial infections: Affecting skin, nails, scalp or mucous membranes; e.g. Tinea versicolor Dermatophytosis: Fungi that affect keratin layer of skin, hair and nail; e.g. Tinea pedis, rign worm infection. Candidiasis: Yeast infections caused by (Malassezia pachydermatis), oral thrush (oral candidiasis), vulvo-vaginitis, nail infection. Systemic/Deep infections: Affecting deeper tissues and organ they usually affect lungs, heart and brain leading to pneumonia, endocarditis and meningitis. Systemic infections are associated with immunocompromised patients, these diseases are serious and often life threatening due to the organ involved. Some of the serious systemic fungal infections in man are candidiasis, cryptococcal meningitis, pulmonary aspergillosis.
    [Show full text]
  • Ambisome® (Amphotericin B) Liposome for Injection
    AmBisome® (amphotericin B) liposome for injection DESCRIPTION AmBisome® for Injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion. Each vial contains 50 mg of amphotericin B, USP, intercalated into a liposomal membrane consisting of approximately 0.64 mg alpha tocopherol, USP; 52 mg cholesterol, NF; 84 mg distearoyl phosphatidylglycerol, sodium salt; 213 mg hydrogenated soy phosphatidylcholine. In addition, 27 mg disodium succinate hexahydrate and 900 mg sucrose, NF are used as a buffer. AmBisome may contain hydrochloric acid and/or sodium hydroxide as pH adjusters. Following reconstitution with Sterile Water for Injection, USP, the resulting pH of the suspension is between 5-6. AmBisome is a true single bilayer liposomal drug delivery system. Liposomes are closed, spherical vesicles created by mixing specific proportions of amphophilic substances such as phospholipids and cholesterol so that they arrange themselves into multiple concentric bilayer membranes when hydrated in aqueous solutions. Single bilayer liposomes are then formed by microemulsification of multilamellar vesicles using a homogenizer. AmBisome consists of these unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. Due to the nature and quantity of amphophilic substances used, and the lipophilic moiety in the amphotericin B molecule, the drug is an integral part of the overall structure of the AmBisome liposomes. AmBisome contains true liposomes that are less than 100 nm in diameter. A schematic depiction of the liposome is presented below. Note: Liposomal encapsulation or incorporation into a lipid complex can substantially affect a drug’s functional properties relative to those of the unencapsulated drug or non-lipid associated drug. In addition, different liposomal or lipid-complex products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component.
    [Show full text]
  • Liposomal Amphotericin B Shows Poor Antifungal Activity Against Candida Tropicalis Biofilms L.J
    Liposomal amphotericin B shows poor antifungal activity against Candida tropicalis biofilms L.J. Marcos- Zambrano1,2 ,P. Escribano1,2,3, E. Bouza1,2,3,4, J. Guinea1,2,3,4 EP0063 1 Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 3 CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain. 4 Medicine Department, Faculty of Medicine, Universidad Complutense de Madrid INTRODUCTION RESULTS Candidemia caused by Candida tropicalis present high mortality rates and is often associated with biofilm formation Most of isolates were classified as high- The three drugs showed activity against the isolates in planktonic form, with on implanted medical devices. biofilm forming according to crystal violet micafungin showing the highest activity (P<0.001). Echinocandins and amphotericin B have shown potent in assay (83%) and showed moderate L-AmB showed the lowest antibiofilm activity (P<0.05). MYC and AmB showed similar vitro antibiofilm activity against C.albicans biofilm, but little is metabolic activity (56%) according to activity when the SMIC50 endpoint was used whereas MYC was the most active agent known about the activity against C. tropicalis biofilms. XTT reduction assay. when the SMIC80 endpoint was used (P<0.001). OBJECTIVE Table 1. Antifungal activity of MYC, AmB and L-AmB against C. tropicalis isolates in plancktonic and sessile forms; SMIC and SMIC are provided for the latter forms. We studied the biofilm production and antifungal 50 80 susceptibility of 54 C. tropicalis isolates causing candidemia (2007 to 2015) to micafungin, amphotericin B, and liposomal Planktonic MIC (mg/L) SMIC50 (mg/L) SMIC80 (mg/L) amphotericin B (Ambisome ®) MYC AmB L-AmB MYC AmB L-AmB MYC AmB L-AmB METHODS Geometric mean 0.026 0.53 0.22 0.72 0.87 1.80 9.82 14.07 30.39 54 C.
    [Show full text]
  • Amphotericin B Amphocil
    Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Amphotericin B Amphocil Abelcet DE/W/009/pdWS/001 Rapporteur: Germany Finalisation procedure (day 120): 24.11.2017 Amphotericin B DE/W/009/pdWS/001 Seite 1 TABLE OF CONTENTS I. Executive Summary ....................................................................................................... 4 II. RecommendatioN .......................................................................................................... 4 III. INTRODUCTION ............................................................................................................. 6 IV. SCIENTIFIC DISCUSSION .............................................................................................. 7 IV.1 Information on the pharmaceutical formulation used in the clinical studies .............. 7 IV.2 Non-clinical aspects ................................................................................................................... 9 IV.3 Clinical aspects .......................................................................................................................... 10 V. MEMBER STATES Overall Conclusion AND RECOMMENDATION ........................... 31 VI. List of Medicinal products and marketing authorisation holders involved ............. 33 Amphotericin B DE/W/009/pdWS/001 Page 2/33 ADMINISTRATIVE INFORMATION Invented name of the medicinal See section VI product(s): INN (or common name) of the active Amphotericin B substance(s):
    [Show full text]
  • Extraction of Essential Oil from River Tea Tree (Melaleuca Bracteata F
    sustainability Article Extraction of Essential Oil from River Tea Tree (Melaleuca bracteata F. Muell.): Antioxidant and Antimicrobial Properties Mursleen Yasin 1,*, Adnan Younis 1, Fahad Ramzan 1, Talha Javed 2,3 , Rubab Shabbir 2 , Hamza Armghan Noushahi 4 , Milan Skalicky 5 , Peter Ondrisik 6 , Marian Brestic 6 , Sabry Hassan 7 and Ayman EL Sabagh 8,* 1 Institute of Horticultural Sciences, University of Agriculture Faisalabad, Faisalabad 38040, Pakistan; [email protected] (A.Y.); fahidfl[email protected] (F.R.) 2 College of Agriculture, Fujian Agriculture and Forestry University, Fuzhou 350002, China; [email protected] (T.J.); [email protected] (R.S.) 3 Department of Agronomy, University of Agriculture Faisalabad, Faisalabad 38040, Pakistan 4 College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; [email protected] 5 Department of Botany and Plant Physiology, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, 16 500 Prague, Czech Republic; [email protected] 6 Department of Plant Physiology, Slovak University of Agriculture, 949 01 Nitra, Slovakia; [email protected] (P.O.); [email protected] (M.B.) 7 Department of Biology, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; [email protected] 8 Department of Agronomy, Faculty of Agriculture, University of Kafrelsheikh, Kafrelsheikh 33516, Egypt * Correspondence: [email protected] (M.Y.); [email protected] (A.E.S.) Citation: Yasin, M.; Younis, A.; Ramzan, F.; Javed, T.; Shabbir, R.; Abstract: Tea tree oil (TTO) from the genus Melaleuca L. has antimicrobial, antibacterial, antifungal, Noushahi, H.A.; Skalicky, M.; and antioxidant properties and is used by the cosmetic, pharmaceutical, and horticultural industries.
    [Show full text]
  • In Vitro Susceptibility to Miltefosine of Leishmania Infantum (Syn. L. Chagasi) Isolates from Different Geographical Areas in Brazil
    microorganisms Article In Vitro Susceptibility to Miltefosine of Leishmania infantum (syn. L. chagasi) Isolates from Different Geographical Areas in Brazil Caroline Ricce Espada 1,† , Erica V. de Castro Levatti 1,† , Mariana Côrtes Boité 2 , Dorcas Lamounier 3, Jorge Alvar 4, Elisa Cupolillo 2, Carlos Henrique Nery Costa 3 , Joelle Rode 5 and Silvia R. B. Uliana 1,* 1 Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil; [email protected] (C.R.E.); [email protected] (E.V.d.C.L.) 2 Laboratório de Pesquisa em Leishmanioses, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil; [email protected] (M.C.B.); [email protected] (E.C.) 3 Universidade Federal do Piauí, Hospital de Doenças Tropicais Natan Portela, Teresina, Piauí 64002-510, Brazil; [email protected] (D.L.); [email protected] (C.H.N.C.) 4 Drugs for Neglected Diseases initiative (DNDi), 1202 Geneva, Switzerland; [email protected] 5 Drugs for Neglected Diseases initiative (DNDi), Rio de Janeiro 20010-020, Brazil; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Treatment of visceral leishmaniasis in Brazil still relies on meglumine antimoniate, with less than ideal efficacy and safety, making new therapeutic tools an urgent need. The oral drug miltefosine was assayed in a phase II clinical trial in Brazil with cure rates lower than previously Citation: Espada, C.R.; Levatti, demonstrated in India. The present study investigated the susceptibility to miltefosine in 73 Brazilian E.V.d.C.; Boité, M.C.; Lamounier, D.; strains of Leishmania infantum from different geographic regions, using intracellular amastigote Alvar, J.; Cupolillo, E.; Costa, C.H.N.; and promastigote assays.
    [Show full text]
  • Amphotericin B: Summary Report
    Amphotericin B: Summary Report Item Type Report Authors Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Yuen, Melissa V.; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Compounding; Food, Drug and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Amphotericin B; Drug compounding; Legislation, Drug; United States Food and Drug Administration Rights Attribution-NonCommercial-NoDerivatives 4.0 International Download date 24/09/2021 02:24:59 Item License http://creativecommons.org/licenses/by-nc-nd/4.0/ Link to Item http://hdl.handle.net/10713/12047 Summary Report Amphotericin B Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATIONS ............................................................................................................... 4 METHODOLOGY .................................................................................................................................
    [Show full text]